Back to Search
Start Over
154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB).
- Source :
-
Annals of Oncology . 2023 Supplement 4, Vol. 34, pS1535-S1535. 1p. - Publication Year :
- 2023
- Subjects :
- *HEPATOCELLULAR carcinoma
*BEVACIZUMAB
*ATEZOLIZUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 34
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 173758172
- Full Text :
- https://doi.org/10.1016/j.annonc.2023.10.289